Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis.

Literature DB >> 30186024

Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis.

Daniella D'Ippolito, Michele Pisano.

Abstract

Dupilumab (Dupixent) for atopic dermatitis.

Entities: Chemical Disease Gene

Year: 2018 PMID： 30186024 PMCID： PMC6110636

Source DB: PubMed Journal: P T ISSN： 1052-1372

10 in total

Review 1. Filaggrin mutations associated with skin and allergic diseases.

Authors: Alan D Irvine; W H Irwin McLean; Donald Y M Leung
Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245

2. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Authors: Andrew Blauvelt; Marjolein de Bruin-Weller; Melinda Gooderham; Jennifer C Cather; Jamie Weisman; David Pariser; Eric L Simpson; Kim A Papp; H Chih-Ho Hong; Diana Rubel; Peter Foley; Errol Prens; Christopher E M Griffiths; Takafumi Etoh; Pedro Herranz Pinto; Ramon M Pujol; Jacek C Szepietowski; Karel Ettler; Lajos Kemény; Xiaoping Zhu; Bolanle Akinlade; Thomas Hultsch; Vera Mastey; Abhijit Gadkari; Laurent Eckert; Nikhil Amin; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos; Brad Shumel
Journal: Lancet Date: 2017-05-04 Impact factor: 79.321

Review 3. Atopic dermatitis: global epidemiology and risk factors.

Authors: Sophie Nutten
Journal: Ann Nutr Metab Date: 2015-04-24 Impact factor: 3.374

Review 4. Atopic dermatitis.

Authors: Stephan Weidinger; Natalija Novak
Journal: Lancet Date: 2015-09-13 Impact factor: 79.321

Review 5. Treatment options for atopic dermatitis.

Authors: Lucinda M Buys
Journal: Am Fam Physician Date: 2007-02-15 Impact factor: 3.292

6. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Authors: Eric L Simpson; Thomas Bieber; Emma Guttman-Yassky; Lisa A Beck; Andrew Blauvelt; Michael J Cork; Jonathan I Silverberg; Mette Deleuran; Yoko Kataoka; Jean-Philippe Lacour; Külli Kingo; Margitta Worm; Yves Poulin; Andreas Wollenberg; Yuhwen Soo; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; Heribert Staudinger; Vera Mastey; Laurent Eckert; Abhijit Gadkari; Neil Stahl; George D Yancopoulos; Marius Ardeleanu
Journal: N Engl J Med Date: 2016-09-30 Impact factor: 91.245

7. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

Authors: Lisa A Beck; Diamant Thaçi; Jennifer D Hamilton; Neil M Graham; Thomas Bieber; Ross Rocklin; Jeffrey E Ming; Haobo Ren; Richard Kao; Eric Simpson; Marius Ardeleanu; Steven P Weinstein; Gianluca Pirozzi; Emma Guttman-Yassky; Mayte Suárez-Fariñas; Melissa D Hager; Neil Stahl; George D Yancopoulos; Allen R Radin
Journal: N Engl J Med Date: 2014-07-10 Impact factor: 91.245

8. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis.

Authors: Heidi H Kong; Julia Oh; Clay Deming; Sean Conlan; Elizabeth A Grice; Melony A Beatson; Effie Nomicos; Eric C Polley; Hirsh D Komarow; Patrick R Murray; Maria L Turner; Julia A Segre
Journal: Genome Res Date: 2012-02-06 Impact factor: 9.043

Review 9. Influences of Environmental Chemicals on Atopic Dermatitis.

Authors: Kwangmi Kim
Journal: Toxicol Res Date: 2015-06

10. Systemic side-effects of topical corticosteroids.

Authors: Sandipan Dhar; Joly Seth; Deepak Parikh
Journal: Indian J Dermatol Date: 2014-09 Impact factor: 1.494

10 in total

7 in total

Review 7. [Recommendations when switching therapy from immunosuppressive drugs to dupilumab in patients with atopic dermatitis].

Authors: Johannes Wohlrab; Ulrich Mrowietz; Stephan Weidinger; Thomas Werfel; Andreas Wollenberg
Journal: Hautarzt Date: 2021-04 Impact factor: 0.751

7 in total

Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis.

Review 1. Filaggrin mutations associated with skin and allergic diseases.

2. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Review 3. Atopic dermatitis: global epidemiology and risk factors.

Review 4. Atopic dermatitis.

Review 5. Treatment options for atopic dermatitis.

6. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

7. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

8. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis.

Review 9. Influences of Environmental Chemicals on Atopic Dermatitis.

10. Systemic side-effects of topical corticosteroids.

1. Corneal Refractive Surgery Considerations in Patients on Dupilumab.

Review 2. Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Review 3. New and Emerging Therapies for Alopecia Areata.

4. Resolution of dupilumab-associated alopecia areata with dosage modification.

5. Model-Based Meta-Analysis to Optimize Staphylococcus aureus‒Targeted Therapies for Atopic Dermatitis.

6. Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase.

Review 7. [Recommendations when switching therapy from immunosuppressive drugs to dupilumab in patients with atopic dermatitis].